Evidence map›Paper›PMID 34451995›Full record

ArticleVaccines2021

Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance.

Yuri Perepliotchikov, Tomer Ziv-Baran, Musa Hindiyeh, Yossi Manor, Danit Sofer, Jacob Moran-Gilad, Laura Stephens, Ella Mendelson, Merav Weil, Ravit Bassal and 11 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Antiviral Activity ofViruses · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Yuri PerepliotchikovCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Tomer Ziv-BaranSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-2589-8473
Musa HindiyehCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Yossi ManorCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Danit SoferCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Jacob Moran-GiladPublic Health Services, MOH, Jerusalem 9101002, Israel.
Laura StephensNational Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
Ella MendelsonCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Merav WeilCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.ORCID 0000-0002-4472-4081
Ravit BassalIsrael Center for Disease Control, Ministry of Health, Gertner Building, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.ORCID 0000-0002-0086-2968
Emilia AnisPublic Health Services, MOH, Jerusalem 9101002, Israel.
Shepherd Roee SingerPublic Health Services, MOH, Jerusalem 9101002, Israel.
Ehud KalinerPublic Health Services, MOH, Jerusalem 9101002, Israel.
Gillian CooperNational Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.
Manasi MajumdarNational Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.ORCID 0000-0002-1413-1509
Michal MarkovichIsrael Center for Disease Control, Ministry of Health, Gertner Building, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.ORCID 0000-0002-2061-5155
Daniela RamCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Itamar GrottoPublic Health Services, MOH, Jerusalem 9101002, Israel.
Ronni GamzuSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Javier MartinNational Institute for Biological Standards and Controls, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.ORCID 0000-0001-5326-7081
Lester M ShulmanCentral Virology Laboratory, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Sheba Medical Center · ILTel Aviv University · ILNational Institute for Biological Standards and Control · GBBen-Gurion University of the Negev · ILHebrew University of Jerusalem · ILIsrael Ministry of Health · IL

Funding

World Health Organization Grant 18- TSA- 032
6 · The paper itself

Abstract

Response to and monitoring of viral outbreaks can be efficiently focused when rapid, quantitative, kinetic information provides the location and the number of infected individuals. Environmental surveillance traditionally provides information on location of populations with contagious, infected individuals since infectious poliovirus is excreted whether infections are asymptomatic or symptomatic. Here, we describe development of rapid (1 week turnaround time, TAT), quantitative RT-PCR of poliovirus RNA extracted directly from concentrated environmental surveillance samples to infer the number of infected individuals excreting poliovirus. The quantitation method was validated using data from vaccination with bivalent oral polio vaccine (bOPV). The method was then applied to infer the weekly number of excreters in a large, sustained, asymptomatic outbreak of wild type 1 poliovirus in Israel (2013) in a population where >90% of the individuals received three doses of inactivated polio vaccine (IPV). Evidence-based intervention strategies were based on the short TAT for direct quantitative detection. Furthermore, a TAT shorter than the duration of poliovirus excretion allowed resampling of infected individuals. Finally, the method documented absence of infections after successful intervention of the asymptomatic outbreak. The methodologies described here can be applied to outbreaks of other excreted viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), where there are (1) significant numbers of asymptomatic infections; (2) long incubation times during which infectious virus is excreted; and (3) limited resources, facilities, and manpower that restrict the number of individuals who can be tested and re-tested.

Indexed as

asymptomatic infectionscomposite sewage samplesinactivated poliovirus vaccineoral poliovirus vaccineoutbreakspoliovirusquantitative environmental surveillancesewagestoolsvaccinationvaccine-derived poliovirus

Identifiers

PMID34451995
PMCPMC8402366
OpenAlexW3188906500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.